ArticleFrontiers in oncology2025
Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Immunothrombotic Extracellular Vesicle mRNA Profile Associated with Thrombosis in Lung Adenocarcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Venous thromboembolism (VTE) occurrence in patients with lung cancer is associated with significant morbidity and mortality. The Khorana Score (KRS) is a validated risk stratification tool developed to estimate risk of VTE in patients with cancer that incorporates clinical and laboratory parameters to calculate individual risk. However, limitations of the KRS in lung cancer have been reported, and identification of other risk factors associated with increased risk of VTE are needed in this population. Methods: We retrospectively evaluated 485 patients with advanced non-small cell lung cancer (NSCLC) and 67 patients with small cell lung cancer (SCLC) treated at our institution between March 2015 and April 2023 to assess the performance of the KRS in estimating risk of VTE in multiple clinically distinct subtypes of lung cancer. Results: The median patient age at diagnosis was 66 years (range, 30-94 years). Patients were predominantly male (51.1%), Caucasian (81%), and had a history of smoking (79.4%). VTE events were observed in 123 patients (22.3%); 51 patients had DVT (41.5%), 50 patients had PE (40.7%), 13 patients had concurrent DVT and PE (7.3%), and other VTE occurred in 9 patients (7.3%). 478 patients (86.6%) had low-risk KRS (score = 0-2) and 74 patients (13.4%) had high-risk KRS (score ≥3). No statistically significant difference in VTE incidence was observed based on baseline KRS. Clinical factors that were noted to be associated with increased risk of VTE were NSCLC histology, Black race, and the presence of an oncogenic driver mutation. No significant differences in overall survival were noted in patients that experienced VTE. Discussion: This study highlights the limitations of the KRS in predicting risk of development of VTE in patients with NSCLC and SCLC and identifies multiple clinical parameters associated with increased risk of VTE. Development of further risk stratification tools incorporating these clinical factors in addition to those in the KRS should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.